New Edition of Guidelines for Involving Communities in HIV Prevention Research Released at International AIDS Conference
GPP Plays Critical Role in Moving HIV Prevention Research Agenda Forward
VIENNA, July 23 /PRNewswire-USNewswire/ -- The draft second edition of The Good Participatory Practice (GPP) Guidelines for Biomedical HIV Prevention Trials were released yesterday at the International AIDS Conference in Vienna by AVAC. The GPP Guidelines aim to provide trial funders, sponsors, and implementers with systematic guidance on how to effectively work with a range of stakeholders as they design and conduct biomedical HIV prevention trials.
The guidelines were developed by AVAC and UNAIDS in consultation with a broad range of global stakeholders who have provided perspectives since the first edition was published in 2007. AVAC and UNAIDS are now seeking feedback on the draft second edition from those with interest and expertise in HIV prevention research until 31 October, after which the final second edition will be published.
Clinical trials are guided by Good Clinical Practice, Good Laboratory Practice, and other guidelines and regulations that cover scientific and general ethical conduct, but global guidelines had not existed for community engagement before the first publication of GPP.
"Recent breakthroughs, including positive results from the CAPRISA 004 microbicide trial, have reenergized prevention research, and around the world, thousands of research participants and hundreds of researchers and trial site staff are working together find new HIV prevention options. Thousands more will be needed as we work to find new solutions to ending the AIDS epidemic," said Mitchell Warren, executive director of AVAC.
"The GPP Guidelines were developed to fill an import